Get Support

Learn Mode

SDGR - Schrodinger Inc

65

$11.55

$0.19 (1.673%)

At market close

$11.31

-$0.24 (-2.069%)

After Hours 4/1/26, 9:39 PM

2.89/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

SDGR

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$746.83M

Industry

Health Care

EPS (TTM)

-$1.41

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

2.92

P/B

2.05

Diluted Shares

73.67M

Ex-Dividend

--

Next Earnings

05-05

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

59.95

FCF Yield

1.67%

Earnings Yield

-13.83%

52 Week Range

Score Card

Explore Scores Tab

2.89

Average

Schrodinger Inc has grown revenue at 23.29% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

4.00

Good

Profitability

1.00

Very Bad

Fin. Health

2.00

Bad

Dividends

--

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:03:35

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-03-19 20:04:11

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-12 16:10:49

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:29:46

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:29:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:28:37

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:28:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:27:15

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:26:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:26:01

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-06 15:18:24

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-05 15:27:29

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$33.60

190.9%

Avg:

$23.57

104.1%

Low:

$13.13

13.7%

(% change is relative to the current stock price: $11.55)

Analyst Recommendations

Go to Analyst Tab

4.13

Good

33%

Strong Buy (5)

47%

Buy (7)

20%

Hold (3)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.schrodinger.com
Address
1540 Broadway, 24th Floor, New York City NEW YORK, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1490978

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 850 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

IPO Date

2020-02-06

Industry

Health Care

Total Employees

850

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Technology

GICS Sub

Health Care Technology

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services